المؤلفون: Z. A. Kolkhidova, I. P. Nikishina, S. I. Glukhova, З. А. Колхидова, И. П. Никишина, С. И. Глухова

المساهمون: Исследование выполнено в рамках фундаментальной научной темы № 1021051302580-4 «Выявление клинических фенотипов и прогнозирование вариантов течения аутоиммунных и аутовоспалительных ревматических заболеваний детского возраста»

المصدر: Rheumatology Science and Practice; Vol 62, No 3 (2024); 309-318 ; Научно-практическая ревматология; Vol 62, No 3 (2024); 309-318 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: прогнозирование ответа на ГИБП, JADI damage index, joint contractures, functional impairment, efficacy of therapy, outcomes of juvenile arthritis, biologics, predicting response to biologics, индекс повреждения JADI, контрактуры суставов, функциональные нарушения, эффективность терапии, исходы ювенильного артрита, генно-инженерные биологические препараты

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3579/2379; Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(7):2092-2102. doi:10.1002/art.21119; Nikishina I, Ruperto N, Kuzmina N, Shelepina T, Illarionova O, Salougina S, et al.; Paediatric Rheumatology International Trials Organisation. The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol. 2001;19(4 Suppl 23):S131-S135.; Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone E, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO). Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: Review of the general methodology. Rheumatol Int. 2018;38(Suppl 1):5-17. doi:10.1007/s00296-018-3944-1; Balay-Dustrude E, Shenoi S. Current validated clinical and patient reported disease outcome measures in juvenile idiopathic arthritis. Open Access Rheumatol. 2023;15:189-206. doi:10.2147/OARRR.S261773; Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819-828. doi:10.1136/annrheumdis-2018-213030; Giancane G, Muratore V, Marzetti V, Quilis N, Benavente BS, Bagnasco F, et al. Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era. Arthritis Res Ther. 2019;21(1):168. doi:10.1186/s13075-019-1950-7; Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al.; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392.; Tangcheewinsirikul S, Sukharomana M, Charuvanij S. Disability and disease-related damage in Thai children and adolescents with juvenile idiopathic arthritis. Pediatr Rheumatol. 2023;21(1):68. doi:10.1186/s12969-023-00852-5; Susic GZ, Stojanovic RM, Pejnovic NN, Damjanov NS, Soldatovic II, Jablanovic DB, et al. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: A prospective outcome study. Clin Exp Rheumatol. 2011;29(2):337-344.; Al-Mayouf SM, Alrasheedi A, Almsellati I, Hashad S, Khawaja K, Abdwani R, et al. Familial aggregation of juvenile idiopathic arthritis with other autoimmune diseases: Impact on clinical characteristics, disease activity status and disease damage. Int J Rheum Dis. 2021;24(8):1080-1085. doi:10.1111/1756-185X.14167; Fazaa A, Ben Salem N, Miladi S, Boussaa H, Souabni L, Quenniche K, et al. Assessment of articular and extra-articular damage in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2022;81(Suppl 1):1735.1-1735. doi:10.1136/annrheumdis2022-eular.2875; Singh YP, Aggarwal A. A modified juvenile arthritis damage index to improve articular damage assessment in juvenile idiopathic arthritis – Enthesitis-related arthritis (JIA-ERA). Clin Rheumatol. 2012;31(5):767-774. doi:10.1007/s10067-011-1928-6; Sarma PK, Misra R, Aggarwal A. Physical disability, articular, and extra-articular damage in patients with juvenile idiopathic arthritis. Clin Rheumatol. 2008;27(10):1261-1265. doi:10.1007/s10067-008-0901-5; Al-Mayouf SM, Hashad S, Khawaja K, Alrasheedi A, Abdwani R, Abushhaiwia A, et al.; Pediatric Arab Rheumatology Group. Cumulative damage in juvenile idiopathic arthritis: A multicenter study from the Pediatric Rheumatology Arab Group. Arthritis Care Res (Hoboken). 2021;73(4):586-592. doi:10.1002/acr.24436; Oliveira-Ramos F, Eusébio M, Martins F, Mourão AF, Furtado C, Campanilho-Marques R, et al. Juvenile idiopathic arthritis in adulthood: Fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open. 2016;2(2):e000304. doi:10.1136/rmdopen-2016-000304; de Oliveira Sato J, Corrente JE, Saad Magalhães C. Progression of articular and extraarticular damage in oligoarticular juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011;29(5):871-877.; Шелепина ТА, Кузьмина НН. Опыт консервативной реабилитации пациентов с ювенильным хроническим артритом. Современная ревматология. 2016;10(1):26-30. doi:10.14412/1996-7012-2016-1-26-30; Кожевников АН, Поздеева НА, Прощенко ЯН, Конев МА, Никитин МС, Прокопович ЕВ, и др. Диагностические критерии поражения локтевого сустава у детей с ювенильным артритом. Гений ортопедии. 2019;25(4):460-467. doi:10.18019/1028-4427-2019-25-4-460-467; https://rsp.mediar-press.net/rsp/article/view/3579

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/3579
https://doi.org/10.47360/1995-4484-2024-309-318

المؤلفون: Smolikho, E. F., Gusev, K. Y., Martynov, A. V., Ustyuzhanin, V. G., Zudova, A. I., Solomatina, L. V., Sentsov, V. G., Смолихо, Е. Ф., Гусев, К. Ю., Мартынов, А. В., Устюжанин, В. Г., Зудова, А. И., Соломатина, Л. В., Сенцов, В. Г.

المصدر: Сборник статей

مصطلحات موضوعية: PARACETAMOL, POISONING, EFFECTIVENESS OF THERAPY, ПАРАЦЕТАМОЛ, ОТРАВЛЕНИЯ, ЭФФЕКТИВНОСТЬ ТЕРАПИИ

وصف الملف: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; Отравления парацетамолом: опыт городского центра токсикологии / Е. Ф. Смолихо, К. Ю. Гусев, А. В. Мартынов [и др.]. – Текст электронный. // Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г. – Екатеринбург : УГМУ, 2023. – C. 219-224.; http://elib.usma.ru/handle/usma/13410

الاتاحة: http://elib.usma.ru/handle/usma/13410

المؤلفون: Yu. S. Filatova, I. N. Solovyov, A. M. Gruzdev, Ю. С. Филатова, И. Н. Соловьев, А. М. Груздев

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2023); 152-158 ; Медицинский Совет; № 21 (2023); 152-158 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: эффективность терапии, hip joints, hyaluronic acid preparations, administration of the drug under ultrasound control, effectiveness of therapy, тазобедренные суставы, препараты гиалуроновой кислоты, введение препарата под контролем УЗИ

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7943/7055; Scheuing WJ, Reginato AM, Deeb M, Acer Kasman S. The burden of osteoarthritis: Is it a rising problem? Best Pract Res Clin Rheumatol. 2023:101836. https://doi.org/10.1016/j.berh.2023.101836.; Molnar V, Matišić V, Kodvanj I, Bjelica R, Jeleč Ž, Hudetz D et al. Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis. Int J Mol Sci. 2021;22(17):9208. https://doi.org/10.3390/ijms22179208.; Fioravanti A, Tenti S, Cheleschi S. Editorial: Year 2020: New Trends in Pharmacological Treatments for Osteoarthritis. Front Pharmacol. 2022;13:892934. https://doi.org/10.3389/fphar.2022.892934.; Ganz R, Parvizi J, Beck M, Leunig M, Nötzli H, Siebenrock KA. Femoroacetabular impingement: a cause for osteoarthritis of the hip. Clin Orthop Relat Res. 2003;(417):112–120. https://doi.org/10.1097/01.blo.0000096804.78689.c2.; Ganz R, Leunig M, Leunig-Ganz K, Harris WH. The etiology of osteoarthritis of the hip: an integrated mechanical concept. Clin Orthop Relat Res. 2008;466(2):264–272. https://doi.org/10.1007/s11999-007-0060-z.; Matsumoto K, Ganz R, Khanduja V. The history of femoroacetabular impingement. Bone Joint Res. 2020;9(9):572–577. https://doi.org/10.1302/2046-3758.99.BJR-2020-0003.; Lespasio MJ, Sultan AA, Piuzzi NS, Khlopas A, Husni ME, Muschler GF, Mont MA. Hip Osteoarthritis: A Primer. Perm J. 2018;22(1):17-084. https://doi.org/10.7812/TPP/17-084.; Sandiford N. Kendoff D, Muirhead-Allwood S. Osteoarthritis of the hip: aetiology, pathophysiology and current aspects of management. Ann Jt. 2019;5:8. https://doi.org/10.21037/aoj.2019.10.06.; Van Berkel AC, Schiphof D, Waarsing JH, Runhaar J, van Ochten JM, Bindels PJE, Bierma-Zeinstra SMA. Course of pain and fluctuations in pain related to suspected early hip osteoarthritis: the CHECK study. Fam Pract. 2022;39(6):1041–1048. https://doi.org/10.1093/fampra/cmac030.; Bothner H, Wik O. Rheology of hyaluronate. Acta Otolaryngol. 1987;104(Suppl. 442):25–30. https://doi.org/10.3109/00016488709102834.; Wang CT, Lin YT, Chiang BL, Lin YH, Hou SM. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage. 2006;14(12):1237–1247. https://doi.org/10.1016/j.joca.2006.05.009.; Yasuda T. Hyaluronan inhibits prostaglandin E2 production via CD44 in U937 human macrophages. Tohoku J Exp Med. 2010;220(3):229–235. https://doi.org/10.1620/tjem.220.229.; Sasaki A, Sasaki K, Konttinen YT, Santavirta S, Takahara M, Takei H et al. Hyaluronate inhibits the interleukin-1beta-induced expression of matrix metalloproteinase (MMP)-1 and MMP-3 in human synovial cells. Tohoku J Exp Med. 2004;204(2):99–107. https://doi.org/10.1620/tjem.204.99.; Тихилов РМ, Лила АМ, Кочиш АЮ, Алексеева ЛИ, Шубняков ИИ, Денисов АО. Коксартроз: клинические рекомендации. М.; 2021. 71 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/666_1.; Clementi D, D’Ambrosi R, Bertocco P, Bucci MS, Cardile C, Ragni P et al. Efficacy of a single intra-articular injection of ultra-high molecular weight hyaluronic acid for hip osteoarthritis: a randomized controlled study. Eur J Orthop Surg Traumatol. 2018;28(5):915–922. https://doi.org/10.1007/s00590-017-2083-9.; Migliore A, Tormenta S, Laganà B, Piscitelli P, Granata M, Bizzi E et al. Safety of intra-articular hip injection of hyaluronic acid products by ultrasound guidance: an open study from ANTIAGE register. Eur Rev Med Pharmacol Sci. 2013;17(13):1752–1759. Available at: https://www.europeanreview.org/article/4552.; Eymard F, Maillet B, Lellouche H, Mellac-Ducamp S, Brocq O, Loeuille D et al. Predictors of response to viscosupplementation in patients with hip osteoarthritis: results of a prospective, observational, multicentre, open-label, pilot study. BMC Musculoskelet Disord. 2017;18(1):3. https://doi.org/10.1186/s12891-016-1359-2.; Koyano G, Jinno T, Koga D, Hoshino C, Okawa A. Intra-articular Injections of Cross-linked Hyaluronic Acid in Japanese Patients with Symptomatic Osteoarthritis of the Hip. Prog Rehabil Med. 2021;6:20210038. https://doi.org/10.2490/prm.20210038.; Migliore A, Frediani B, Gigliucci G, Foti C, Crimaldi S, De Lucia O, Iolascon G. Efficacy of a Single Intra-Articular HYMOVIS ONE Injection for Managing Symptomatic Hip Osteoarthritis: A 12-Month Follow-Up Retrospective Analysis of the ANTIAGE Register Data. Orthop Res Rev. 2020;12:19–26. https://doi.org/10.2147/ORR.S239355.; Pogliacomi F, Schiavi P, Paraskevopoulos A, Leigheb M, Pedrazzini A, Ceccarelli F, Vaienti E. When is indicated viscosupplementation in hip osteoarthritis? Acta Biomed. 2018;90(Suppl. 1):67–74. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503407/.; Migliore A, Massafra U, Bizzi E, Vacca F, Martin-Martin S, Granata M et al. Comparative, double-blind, controlled study of intra-articular hyaluronic acid (Hyalubrix) injections versus local anesthetic in osteoarthritis of the hip. Arthritis Res Ther. 2009;11(6):R183. https://doi.org/10.1186/ar2875.; Ye Y, Zhou X, Mao S, Zhang J, Lin B. Platelet rich plasma versus hyaluronic acid in patients with hip osteoarthritis: A meta-analysis of randomized controlled trials. Int J Surg. 2018;53:279–287. https://doi.org/10.1016/j.ijsu.2018.03.078.; Abate M, Scuccimarra T, Vanni D, Pantalone A, Salini V. Femoroacetabular impingement: is hyaluronic acid effective? Knee Surg Sports Traumatol Arthrosc. 2014;22(4):889–892. https://doi.org/10.1007/s00167-013-2581-1.; Lee YK, Lee GY, Lee JW, Lee E, Kang HS. Intra-Articular Injections in Patients with Femoroacetabular Impingement: a Prospective, Randomized, Double-blind, Cross-over Study. J Korean Med Sci. 2016;31(11):1822–1827. https://doi.org/10.3346/jkms.2016.31.11.1822.; Conrozier T, Monfort J, Chevalier X, Raman R, Richette P, Diraçoglù D et al. EUROVISCO Recommendations for Optimizing the Clinical Results of Viscosupplementation in Osteoarthritis. Cartilage. 2020;11(1):47–59. https://doi.org/10.1177/1947603518783455.; Филатова ЮС, Соловьев ИН. Гиалуроновая кислота в лечении остеоартрита различных локализаций. Обзор литературы. Терапевтический архив. 2022;94(8):1014–1019. https://doi.org/10.26442/00403660.2022.08.201790.; Филатова ЮС, Гауэрт ВР. Гиалуроновая кислота при внутрисуставном введении: зависимость эффекта от молекулярной массы. РМЖ. Медицинское обозрение. 2021;5(3):156–161. https://doi.org/10.32364/2587-6821-2021-5-3-156-161.; Филатова ЮС, Соловьев ИН. Пациент с остеоартритом коленных суставов: тактика ведения в амбулаторных условиях. Медицинский совет. 2021;(2):86–93. https://doi.org/10.21518/2079-701X-2021-2-86-93.; https://www.med-sovet.pro/jour/article/view/7943

الاتاحة: https://www.med-sovet.pro/jour/article/view/7943
https://doi.org/10.21518/ms2023-407

المؤلفون: Chebotarev V.V., Zemtsov M.A., Odinets A.V., Chebotareva N.V.

المصدر: Vestnik dermatologii i venerologii; Vol 97, No 1 (2021); 8-15 ; Вестник дерматологии и венерологии; Vol 97, No 1 (2021); 8-15 ; 2313-6294 ; 0042-4609 ; 10.25208/vdv.11

مصطلحات موضوعية: syphilis, penicillin, treatment regimens, experimental studies, effectiveness of therapy, сифилис, пенициллин, схемы лечения, экспериментальные исследования, эффективность терапии

وصف الملف: application/pdf

Relation: https://vestnikdv.ru/jour/article/view/1179/1168; https://vestnikdv.ru/jour/article/view/1179/1178; https://vestnikdv.ru/jour/article/downloadSuppFile/1179/498; https://vestnikdv.ru/jour/article/view/1179

الاتاحة: https://vestnikdv.ru/jour/article/view/1179
https://doi.org/10.25208/vdv1179

المؤلفون: A. S. Avdeeva, E. V. Chetina, G. A. Markova, E. L. Nasonov, А. С. Авдеева, Е. В. Четина, Г. А. Маркова, Е. Л. Насонов

المصدر: Modern Rheumatology Journal; Том 15, № 5 (2021); 12-17 ; Современная ревматология; Том 15, № 5 (2021); 12-17 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: эффективность терапии, interferon-stimulated genes, interferon signature, disease activity, the effectiveness of therapy, интерферон-стимулированные гены, интерфероновый «автограф», активность заболевания

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1191/1145; https://mrj.ima-press.net/mrj/article/view/1191/1167; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: Гэотар-Медиа; 2008. С. 290-331.; Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-61.; De Weerd NA, Nguyen T. The interferons and their receptors—distribution and regulation. Immunol Cell Biol. 2012 May;90(5): 483-91. doi:10.1038/icb.2012.9. Epub 2012 Mar 13.; Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol. 2010 Jan; 6(1):40-9. doi:10.1038/nrrheum.2009.237.; Kotenko SV, Gallagher G, Baurin VV, et al. IFN- λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003 Jan;4(1):69-77. doi:10.1038/ni875. Epub 2002 Dec 16.; Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006 May;80(9): 4501-9. doi:10.1128/JVI.80.9.4501-4509.2006.; Honda K, Takaoka A, Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006 Sep;25(3):349-60. doi:10.1016/j.immuni.2006.08.009.; Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003 Aug; 19(2):225-34. doi:10.1016/s1074-7613 (03)00208-5.; Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009 Jul 6;206(7):1589-602. doi:10.1084/jem.20090247. Epub 2009 Jun 29.; Green DS, Young HA, Valencia JC. Current prospects of type II interferon γ signaling and autoimmunity. J Biol Chem. 2017 Aug 25;292(34):13925-33. doi:10.1074/jbc.R116.774745. Epub 2017 Jun 26.; Le Bon A, Thompson C, Kamphuis E, et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol. 2006 Feb 15;176(4):2074-8. doi:10.4049/jimmunol.176.4.2074.; Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017 Oct 1;56(10): 1662-75. doi:10.1093/rheumatology/kew431.; Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity: type I interferonopathies. Ann N Y Acad Sci. 2011 Nov;1238:91-8. doi:10.1111/j.1749-6632.2011.06220.x.; Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000 Jul;43(7):1431-42. doi:10.1002/1529-0131(200007)43:73.0.CO;2-E.; Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010 Dec;62(12):3607-14. doi:10.1002/art.27702.; Raterman HG, Vosslamber S, De RS, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi:10.1186/ar3819.; Tchetina EV, Poole AR, EM Zaitseva, et al. Differences in mTOR (mammalian target of rapamycin) gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity. Arthritis. 2013;2013:461486. doi:10.1155/2013/461486. Epub 2013 Jun 25.; Lubbers J, Brink M, van de Stadt LA, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis. 2013 May;72(5):776-80. doi:10.1136/annrheumdis-2012-202753. Epub 2013 Feb 23.; Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007 Aug;66(8): 1008-14. doi:10.1136/ard.2006.063412. Epub 2007 Jan 12.; Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011 Nov;70(11): 2029-36. doi:10.1136/ard.2011.150326. Epub 2011 Jul 28.; Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-β/α ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010 Feb;62(2):392-401. doi:10.1002/art.27226.; Wampler Muskardin T, Vashisht P, Dorschner JM, et al. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016 Oct;75(10):1757-62. doi:10.1136/annrheumdis-2015-208001. Epub 2015 Nov 6.; De Jong TD, Vosslamber S, Mantel E, et al. Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases. Arthritis Res Ther. 2016 Feb 17;18:49. doi:10.1186/s13075-016-0946-9.; https://mrj.ima-press.net/mrj/article/view/1191

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1191
https://doi.org/10.14412/1996-7012-2021-5-12-17

المؤلفون: B. B. Pinkhasov, V. G. Selyatitskaya, Yu. V. Lutov, D. A. Deev

المصدر: Бюллетень сибирской медицины, Vol 17, Iss 4, Pp 122-130 (2018)

مصطلحات موضوعية: риск развития, тяжесть, балльная оценка, эффективность терапии, Medicine

وصف الملف: electronic resource

Relation: https://bulletin.ssmu.ru/jour/article/view/1985; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684

URL الوصول: https://doaj.org/article/3c0e5a37bfe840dbbea572bc7b7d768b

المؤلفون: Ольга Юрьевна Цыганкова, Елена Николаевна Кравченко, Лариса Владимировна Куклина, Светлана Ивановна Филатова, Владимир Евгеньевич Савкулич

المصدر: Мать и дитя в Кузбассе, Vol 19, Iss 1, Pp 27-31 (2018)

مصطلحات موضوعية: впч ассоциированная патология шейки матки, элиминация вируса, эффективность терапии, Pediatrics, RJ1-570, Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

Relation: http://mednauki.ru/index.php/MD/article/view/183; https://doaj.org/toc/1991-010X; https://doaj.org/toc/2542-0968

URL الوصول: https://doaj.org/article/d6c2520a3f21438cb44518d017abf4fb

المؤلفون: T. E. Tyulkova, N. D. Pirogova, R. M. Bekova

المصدر: Туберкулез и болезни лёгких, Vol 95, Iss 12, Pp 39-43 (2018)

مصطلحات موضوعية: туберкулез, приверженность лечению, комбинированные препараты с фиксированными дозами, эффективность терапии, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

Relation: https://www.tibl-journal.com/jour/article/view/1073; https://doaj.org/toc/2075-1230; https://doaj.org/toc/2542-1506

URL الوصول: https://doaj.org/article/2af53d29344d4d7c8d6da9fe3d806ecc

المؤلفون: E. M. Zhukovа, E. P. Myshkovа, T. I. Petrenko, T. A. Reykhrud

المصدر: Туберкулез и болезни лёгких, Vol 95, Iss 12, Pp 22-27 (2018)

مصطلحات موضوعية: множественная/широкая лекарственная устойчивость возбудителя, деструктивный туберкулез легких, деринат, эффективность терапии, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

Relation: https://www.tibl-journal.com/jour/article/view/1070; https://doaj.org/toc/2075-1230; https://doaj.org/toc/2542-1506

URL الوصول: https://doaj.org/article/b5cd13dc53754b18b031d0ad14711e1a

المؤلفون: Yu. E. Ovchinnikovа, A. A. Stаrshinovа, I. F. Dovgаlyuk

المصدر: Туберкулез и болезни лёгких, Vol 95, Iss 7, Pp 48-53 (2017)

مصطلحات موضوعية: туберкулез органов дыхания, дети, комбинированный препарат с фиксированными дозами, нежелательные реакции, эффективность терапии, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

Relation: https://www.tibl-journal.com/jour/article/view/1023; https://doaj.org/toc/2075-1230; https://doaj.org/toc/2542-1506

URL الوصول: https://doaj.org/article/32ab663a0c0d4d77b31424db6de6fb75

المؤلفون: Shamro, V. A., Moiseenko, M. V., Askerova, M. G., Шамро, В. А., Моисеенко, М. В., Аскерова, М. Г.

المصدر: Сборник статей

مصطلحات موضوعية: THREAT OF ABORTION, PREGNANCY, EFFICIENCY OF THE THERAPY, БЕРЕМЕННОСТЬ, УГРОЗА ПРЕРЫВАНИЯ БЕРЕМЕННОСТ, ЭФФЕКТИВНОСТЬ ТЕРАПИИ

وصف الملف: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей IV Международной научно-практической конференции молодых учёных и студентов, IV Всероссийского форума медицинских и фармацевтических вузов «За качественное образование», (Екатеринбург, 10-12 апреля 2019): в 3-х т. - Екатеринбург: УГМУ, CD-ROM.; Шамро, В. А. Анализ факторов риска невынашивания беременности и оценка эффективности терапии угрозы прерывания беременности в I и II триместрах на этапе стационара / В. А. Шамро, М. В. Моисеенко, М. Г. Аскерова // Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей IV Международной научно-практической конференции молодых учёных и студентов, IV Всероссийского форума медицинских и фармацевтических вузов «За качественное образование», (Екатеринбург, 10-12 апреля 2019): в 3-х т. - Екатеринбург: УГМУ, CD-ROM. – 2019. – Т.1. – С. 200-204.; http://elib.usma.ru/handle/usma/3710

الاتاحة: http://elib.usma.ru/handle/usma/3710

المؤلفون: A. Zastrozhina K., I. Zakharova N., D. Sychev A., А. Застрожина K., И. Захарова Н., Д. Сычев А.

المساهمون: Работа выполнена на базе Государственного бюджетного учреждения здравоохранения города Москвы «Детская государственная поликлиника №42 Департамента здравоохранения города Москвы»

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2019); 160-165 ; Медицинский Совет; № 11 (2019); 160-165 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-11

مصطلحات موضوعية: bronchial asthma, adherence to therapy, efficacy of therapy, inhaled glucocorticosteroids, бронхиальная астма, приверженность терапии, эффективность терапии, ингаляционные глюкокортикостероиды

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/3098/3018; Поликарпов А.В., Александрова Г.А., Голубева Н.А. Статистические материалы. Общая заболеваемость детского населения России (0 – 14 лет) в 2017 году. Часть VI. 2018г., 144 с. Доступен по ссылке: https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskieiinformatsionnye-materialy/statisticheskiysbornik2017-god; Mallola J., Crane J., von Mutius E., Odhiambo J., Keil U., Stewart A., the ISAAC Phase Three Study Group The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73–85.; Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 5-е изд., перераб. и доп. М.: Оригиналмакет, 2017.; Global Strategy for Asthma Management and Prevention (2018 update).; Федеральные клинические рекомендации по лечению атопической бронхиальной астмы, 2015.; Федеральные клинические рекомендации Бронхиальная астма у детей. 2017 год.; Застрожина А.К., Сычев Д.А., Зайцева С.В., Архипов В.В., Панферова О.О., Каленов С.Е., Соболева О.И. Фармакоэпидемиологический анализ у детей с бронхиальной астмой в амбулаторно-поликлинической практике: ретроспективное исследование. Consilium Medicum. Педиатрия. (Прил.). 2018;04:72-82.; Rabe K.F. et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000;16:802.; Price D., Fletcher M., and van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Medю 2014, 24:14009. https://doi.org/10.1038/npjpcrm.2014.9.; Ненашева Н.М. Контроль бронхиальной астмы у подростков. Педиатрическая фармакология. 2008;5(3):98-103.; Кораблева А.А. Оптимизация фармакотерапии бронхиальной астмы у детей на основании фармакоэпидемиологических и лабораторноклинических исследований [Текст]: автореферат дис. . канд. мед. наук : 14.00.25, 14.00.09; науч. рук.: Л.Е. Зиганшина, О.И. Пикуза; ГОУ ДПО Казан. гос. мед. акад., ГОУ ВПО Казан. гос. мед. ун-т. Казань, 2004. 18 с. : ил. Библиогр.: с. 17-18.; Цой А.Н., Архипов В.В. Фармакоэпидемио логический анализ амбулаторной терапии бронхиальной астмы у взрослых и подростков в Москве в 2003 г. Consilium Medicum. 2004;04: 248-254.; Скоков М.В., Филатова Ю.И. Комплаенс и контроль бронхиальной астмы. Молодой ученый. 2014;17:195-200. URL https://moluch.ru/archive/76/12968/; Bender B., Milgrom H., Rand C.S., Ackerson L. Psychological factors associated with medication nonadherence in asthmatic children. Journal of Asthma. 1998;35(4):347-353.; Mosnaim G., Li H., Martin M., Richardson D., Belice P.J., Avery E., Ryan N., Bender B., Powell L. Factors associated with levels of adherence to inhaled corticosteroids in minority adolescents with asthma. Ann Allergy Asthma Immunol. 2014 Feb;112(2):116-20. doi:10.1016/j.anai.2013.11.021. Epub 2013 Dec 21.; Gamble J., Stevenson M., McClean E., Heaney L.G. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009 Nov 1;180(9):817-22. doi:10.1164/rccm.200902-0166OC. Epub 2009 Jul 30.; Krishnan J.A., Riekert K.A., McCoy J.V., Stewart D.Y., Schmidt S., Chanmugam A., et al. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am J Respir Crit Care Med. 2004;170(12):1281-1285.; Williams L.K., Pladevall M., Xi H., Peterson E.L., Joseph C., Lafata J.E., et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114(6):1288-1293.; Ильенкова Н.А., Черепанова И.В., Вохмина Т.А. Проблемы приверженности терапии у детей с бронхиальной астмой. Педиатрическая фармакология. 2016;13(6):565-570.; World Health Organisation (2003): Adherence to longterm therapy, evidence for action. Geneva: [Электрон. Ресурс]. Доступ http://www.who.int2.; Howell G. Nonadherence to medical therapy in asthma: risk factors, barriers, and strategies for improving. J Asthma. 2008;45(9):723–729. doi:10.1080/02770900802395512.; Прикладная фармакоэпидемиология. Под ред. Петрова В.И. М.: ГЭОТАР-Медиа; 2008. 384 с.; Juniper E.F., Gruffydd-Jones K., Ward S., et al. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J. 2010;36:1410-1416.; Nathan R.A., Sorkness C.A., Kosinski M., et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59-65.; Liu A.H., Zeiger R., Sorkness C., et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol. 2007;119:817-25.; https://www.med-sovet.pro/jour/article/view/3098

الاتاحة: https://www.med-sovet.pro/jour/article/view/3098
https://doi.org/10.21518/2079-701X-2019-11-160-165

المؤلفون: Замахина, О. В., Бунова, С. С., Николаев, Н. А.

مصطلحات موضوعية: медицина, кардиология, бисопролол, эффективность терапии, ишемическая болезнь сердца, инфаркт миокарда, обсервационное испытание

Relation: Замахина, О.В. Эффективность терапии бисопрололом больных стабильной ишемической болезнью сердца, перенесших инфаркт миокарда, с учетом прогноза его эффективности и расчетом индивидуальной стартовой дозы: результаты проспективного обсервационного испытания / О.В. Замахина, С.С. Бунова, Н.А. Николаев // Современные проблемы науки и образования : электрон. науч. журн. - 2019. - № 4. - С. 39-48. - Библиогр.: с. 47-48; http://dspace.bsu.edu.ru/handle/123456789/45422

الاتاحة: http://dspace.bsu.edu.ru/handle/123456789/45422

المؤلفون: N. F. Puchinyan, N. V. Furman, A. R. Kiselev, Ya. P. Dovgalevsky

المصدر: Рациональная фармакотерапия в кардиологии, Vol 5, Iss 6, Pp 41-46 (2016)

مصطلحات موضوعية: острый коронарный синдром, антиагреганты, эффективность терапии, сердечно-сосудистые осложнения, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/734; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

URL الوصول: https://doaj.org/article/f50f798faa444b879e814e36e5526f1d

المؤلفون: A. V. Mordyik, O. G. Ivanova, L. A. Nagibina, S. V. Sitnikova, G. Zh. Sagalbaeva

المصدر: Туберкулез и болезни лёгких, Vol 0, Iss 10, Pp 69-75 (2015)

مصطلحات موضوعية: деструктивный инфильтративный туберкулез легких, иммунорепарация, эффективность терапии, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

Relation: https://www.tibl-journal.com/jour/article/view/811; https://doaj.org/toc/2075-1230; https://doaj.org/toc/2542-1506

URL الوصول: https://doaj.org/article/c399762df19947bd8897090d2b256694

المؤلفون: G. A. Baryshnikova, S. A. Chorbinskaya, I. J. Stepanova

المصدر: Евразийский Кардиологический Журнал, Vol 0, Iss 3, Pp 62-66 (2015)

مصطلحات موضوعية: cardiovascular risks, polypill, therapy effectiveness, compliance, ekvamer, сердечно-сосудистый риск, полипилюля, эффективность терапии, комплаенс, эквамер, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://www.heartj.asia/jour/article/view/5648; https://doaj.org/toc/2225-1685; https://doaj.org/toc/2305-0748

URL الوصول: https://doaj.org/article/b08be7e0d21f40dd8af620b70c28eb6c

المؤلفون: Цыганкова, Ольга Юрьевна, Кравченко, Елена Николаевна, Куклина, Лариса Владимировна, Филатова, Светлана Ивановна, Савкулич, Владимир Евгеньевич

المصدر: Mother and Baby in Kuzbass; № 1 (2018): март; 27-31 ; Мать и Дитя в Кузбассе; № 1 (2018): март; 27-31 ; 2542-0968 ; 1991-010X

مصطلحات موضوعية: HPV associated pathology of the cervix, elimination of the virus, the effectiveness of therapy, ВПЧ ассоциированная патология шейки матки, элиминация вируса, эффективность терапии

وصف الملف: application/pdf; text/html

Relation: http://mednauki.ru/index.php/MD/article/view/183/340; http://mednauki.ru/index.php/MD/article/view/183/363; http://mednauki.ru/index.php/MD/article/view/183

الاتاحة: http://mednauki.ru/index.php/MD/article/view/183

المؤلفون: A. Avdeeva S., А. Авдеева С.

المصدر: Rheumatology Science and Practice; Vol 56, No 4 (2018); 494-499 ; Научно-практическая ревматология; Vol 56, No 4 (2018); 494-499 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20184

مصطلحات موضوعية: calprotectin, rheumatoid arthritis, spondyloarthritis, disease activity, efficiency of therapy, кальпротектин, ревматоидный артрит, спондилоартриты, активность заболевания, эффективность терапии

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2596/1739; Ometto F, Friso L, Astorri D, et al. Calprotectin in rheumatic diseases. Exper Biol Med. 2017;242:859-73.; Chen YS, Yan W, Geczy CL, et al. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R39. doi:10.1186/ar2645; Loser K, Vogl T, Voskort M, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010;16:713-7. doi:10.1038/nm.2150; Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol. 1998;160:1427-35.; Uchida T, Fukawa A, Uchida M, et al. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res. 2002;1:495-9. doi:10.1021/pr025531w; Van Lent PL, Grevers L, Blom AB, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis. 2008;67:1750-8. doi:10.1136/ard.2007.077800; Viemann D, Strey A, Janning A, et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood. 2005;105:2955-62.; Vogl T, Ludwig S, Goebeler M, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104:4260-8. doi:10.1182/blood-2004-02-0446; Averill MM, Barnhart S, Becker L, et al. S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and den-dritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation. 2011;123:1216-26. doi:10.1161/CIR-CULATIONAHA.110.985523; Chih-Ru L, Tong-You WW, Hsien-Yu T, et al. Glycosylation-dependent interaction between CD69 and S100A8/S100A9 complex is required for regulatory T-cell differentiation. FASEB J. 2015;29:5006-17. doi:10.1096/fj.15-273987; Kopec-Medrek M, Widuchowska M, Kucharz E. Calprotectin in rheumatic diseases: a review. Reumatologia. 2016;54:6.; Morrow DA, Wang Y, Croce K, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008;155(1):49-55. doi:10.1016/j.ahj.2007.08.018; Peng WH, Jian WX, Li HL, et al. Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol. 2011 May 18;10:41.; Garcia-Arias M, Pascual-Salcedo D, Ramiro S, et al. Calprotectin in rheumatoid arthritis. Mol Diagn Ther. 2013;17:49-56.; Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303:1266-73. doi:10.1001/jama.2010.375; Holzinger D, Frosch M, Kastrup A, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:974-80. doi:10.1136/annrheumdis-2011-200598; Wittkowski H, Kuemmerle-Deschner JB, Austermann J, et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis. 2011;70:2075-81. doi:10.1136/ard.2011.152496; Jonsson MK, Hammer HB, Nordal HH, et al. Calprotectin levels correlate with inflammation in early rheumatoid arthritis before disease-modifying antirheumatic drug treatment and after 12 months of treatment [abstract]. Arthritis Rheum. 2016;68 Suppl 10. https://acrabstracts.org/abstract/calprotectin-levels-correlate-with-inflammation-in-early-rheumatoid-arthritis-before-disease-modifying-antirheumatic-drug-treatment-and-after-12-months-of-treatment/. Accessed July 17, 2018.; Jonsson MK, Sundlisaeter NP, Nordal HH, et al. Calprotectin as a marker of inflmmation in patients with early rheumatoid arthritis. Ann Rheum Dis. 2017;76:2031-7. doi:10.1136/annrheumdis-2017-211695; Soliman A, Elnadya B, Shakerc R, Mansour A. Potential role of calprotectin as a monitoring biomarker for clinical and sonographic activity and treatment outcome in recent-onset rheumatoid arthritis. Egypt Rheumatol Rehabil. 2016;43(3). doi:10.4103/1110-161X.189824; Inciarte-Mundo J, Victoria Hernandez M, Ruiz-Esquide V, et al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res. 2016;68:899-906. doi:10.1002/acr.22795; Inciarte-Mundo J, Ruiz-Esquide V, Hernandez MV, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology. 2015;54:2239-43.; Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66:1093-7. doi:10.1136/ard.2006.064741; Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499-505. doi:10.1136/annrheumdis-2013-203923; Nair SC, Welsing PMJ, Choi IYK, et al. A personalized approach to biological therapy using prediction of clinical response based on MRP8/14 serum complex levels in rheumatoid arthritis patients. PLoS ONE. 2016;11(3): e0152362. doi:10.1371/journal.pone.0152362; Choi IY, Gerlag DM, Holzinger D, et al. From synovial tissue to peripheral blood: Myeloid related protein 8/14 is a sensitive bio-marker for effective treatment in early drug development in patients with rheumatoid arthritis. PLoS ONE. 2014;9(8):e106253. doi:10.1371/journal.pone.0106253; Tweehuysen L, den Broeder N, Joosten LAB, et al. No added predictive value of serum calprotectin for treatment response to adalimumab or etanercept in RA patients [abstract]. Arthritis Rheum. 2017;69 Suppl 10. https://acrabstracts.org/abstract/no-added-predictive-value-of-serum-calprotectin-for-treatment-response-to-adalimumab-or-etanercept-in-ra-patients/. Accessed July 17, 2018.; Пчелинцева АО, Жорняк АП, Иониченок НГ и др. Динамика уровня кальпротектина, его взаимосвязь с клинико-лабораторными параметрами активности, значение для прогнозирования ответа на терапию у больных ревматоидным артритом на фоне лечения этанерцептом (исследование ЭТАЛОН). Научно-практическая ревматология. 2015;53(4):379-84 doi:10.14412/1995-4484-2015-379-384; Moncrieffe H, Ursu S, Holzinger D, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford). 2013;52:1467-76. doi:10.1093/rheumatology/ket152; Smith S, Plant D, Eyre S, et al. The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology. 2017;56:1019-24.; Obry A, Lequerre T, Hardouin J, et al. Identification of S100A9 as Biomarker of Responsiveness to the Methotrexate/Etanercept Combination in Rheumatoid Arthritis Using a Proteomic Approach. PLoS ONE. 2014;9(12):e115800. doi:10.1371/journal.pone.0115800; Inciarte-Mundo J, Ramirez J, Hernandez MV, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016;18:160. doi:10.1186/s13075-016-1032-z; Guo Q, Zha X, Li C, et al. Serum calprotectin - a promising diagnostic marker for adult-onset Still's disease. Clin Rheumatol. 2016;35:73-9. doi:10.1007/s10067-015-3108-6; Kruithof E, De Rycke L, Vandooren B, et al. Identification of syn-ovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum. 2006;54:1795-804. doi:10.1002/art.21914; De Rycke L, Baeten D, Foell D, et al. Differential expression and response to anti-TNF treatment of infiltrating versus resident tissue macrophage subsets in auto-immune arthritis. J Pathol. 2005;206:17-27. doi:10.1002/path.1758; Oktayoglu P, Bozkurt M, Mete N, et al. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with anky-losing spondylitis and its association with disease activity and quality of life. J Invest Med. 2014;62:880-4. doi:10.1097/JIM.0000000000000095; Turina MC, Yeremenko N, Paramarta JE, et al. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16:413. doi:10.1186/s13075-014-0413-4; Duran A, Kobak S, Sen N, et al. Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Bosn J Basic Med Sci. 2015;16:71-4.; Klingberg E, Carlsten H, Hilme E, et al. Calprotectin in ankylosing spondylitis – frequently elevated in faeces, but normal in serum. Scand J Gastroenterol. 2012;47:435-44.; Cypers H, Varkas G, Beeckman S, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016;75:1357-62. doi:10.1136/annrheumdis-2015-208025; Turina MC, Sieper J, Yeremenko N, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis. 2014;73:1746-8.; Huang J, Yin Z, Song G, et al. Discriminating Value of Calprotectin in Disease Activity and Progression of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis. Dis Markers. 2017;2017:Article ID 7574147. 5 p. doi:10.1155/2017/7574147; Van Praet L, Jacques P, van den Bosch F, Elewaut D. The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol. 2012 Apr 17;8(5):288-95.; https://rsp.mediar-press.net/rsp/article/view/2596

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2596
https://doi.org/10.14412/1995-4484-2018-494-499

المؤلفون: A. Avdeeva S., А. Авдеева С.

المصدر: Rheumatology Science and Practice; Vol 55, No 6 (2017); 655-661 ; Научно-практическая ревматология; Vol 55, No 6 (2017); 655-661 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20176

مصطلحات موضوعية: rheumatoid arthritis, disease activity, C-X-C chemokines, IFN-γ-induced protein 10, effectiveness of therapy, biomarkers, ревматоидный артрит, активность заболевания, C-X-C хемокины, ИФНγ-индуцируемый белок 10, эффективность терапии, биомаркеры

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2471/1641; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional'noe rukovodstvo [Rheumatology: National guidelance]. Moscow: GEOTAR-Media; 2008. P. 290-331].; Firestein G. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356-61. doi:10.1038/nature01661; Choy E, Panayi G. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-16.; Weyand C, Goronzy J. Ectopic germinal center formation in rheumatoid synovitis. Ann NY Acad Sci. 2003;987:140-9. doi:10.1111/j.1749-6632.2003.tb06042.x; Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009;8(5):379-83.; Schulthess FT, Paroni F, Sauter NS, et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab. 2009;9(2):125-39. doi:10.1016/j.cmet.2009.01.003; Rotondi M, Chiovato L, Romagnani S, et al. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28(5):492-520. doi:10.1210/er.2006-0044; Soejima K, Rollins BJ. A functional IFN--inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. J Immunol. 2001;167:6576-82. doi:10.4049/jimmunol.167.11.6576; Campanella GS, Lee EM, Sun J, Luster AD. CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). J Biol Chem. 2003;278:17066-74. doi:10.1074/jbc.M212077200; Campanella GS, Colvin RA, Luster AD. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One. 2010;5:e12700. doi:10.1371/journal.pone.0012700; Shimada A, Morimoto J, Kodama K, et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care. 2001;24:510-5. doi:10.2337/diacare.24.3.510; Nicoletti F, Conget I, DiMauro M, et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia. 2002;45:1107-10. doi:10.1007/s00125-002-0879-5; Nakagawa Y, Shimada A, Oikawa Y, et al. Two cases of «fulminant» type 1 diabetes suggesting involvement of autoimmunity. Ann N Y Acad Sci. 2003;1005:359-61. doi:10.1196/annals.1288.059; Gabbay MA, Sato MN, Duarte AJ, Dib SA. Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin Exp Immunol. 2012;168:60-7. doi:10.1111/j.1365-2249.2011.04538.x; Kemp EH, Metcalfe RA, Smith KA, et al. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol. 2003;59:207-13. doi:10.1046/j.1365-2265.2003.01824.x; Kimura H, Kimura M, Rose NR, Caturegli P. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto's thyroiditis. Exp Mol Pathol. 2004;77:161-7.; Antonelli A, Rotondi M, Fallahi P, et al. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab. 2004;89:5496-9. doi:10.1210/jc.2004-0977; Hanaoka R, Kasama T, Muramatsu M, et al. A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther. 2003;5:R74-81.; Prud'homme GJ, Kono DH, Theofilopoulos AN. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-10 and interferon gamma mRNA in the lymph nodes of lupus-prone mice. Mol Immunol. 1995;32:495-503. doi:10.1016/0161-5890(95)00024-9; Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001;194:398-405. doi:10.1002/1096-9896(200108)194:43.0.CO;2-S; Wenzel J, Wö renkä mper E, Freutel S, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205:435-42.; Meller S, Winterberg F, Gilliet M, et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 2005;52:1504-16. doi:10.1002/art.21034; Gambichler T, Genc Z, Skrygan M, et al. Cytokine and chemokine ligand expression in cutaneous lupus erythematosus. Eur J Dermatol. 2012;22:319-23.; Narumi S, Takeuchi T, Kobayashi Y, Konishi K. Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine. 2000;12:1561-5.; Fujii H, Shimada Y, Hasegawa M, et al. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci. 2004;35:43-51. doi:10.1016/j.jdermsci.2004.03.001; Giuggioli D, Manfredi A, Colaci M, et al. Systemic sclerosis and cryoglobulinemia: our experiencewith overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev. 2013;12:1058-63. doi:10.1016/j.autrev.2013.06.013; Ferri C, Zignego AL. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol. 2000;12:53-60. doi:10.1097/00002281-200001000-00009; Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med. 2002;137:571-80. doi:10.7326/0003-4819-137-7-200210010-00008; Ferri C, Pileri S, Zignego AL. Hepatitis C virus infection and in non-Hodgkin's lymphoma. In: Goedert J, editor. Infectious causes of cancer. Targets for intervention. Totowa, New Jersey: The Human Press Inc.; 2000. P. 349-68.; Wedderburn LR, Robinson N, Patel A, et al. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum. 2000;43:765-74. doi:10.1002/1529-0131(200004)43:43.0.CO;2-B; Ruth JH, Rottman JB, Katschke Jr KJ, et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum. 2001;44:2750-60. doi:10.1002/1529-0131(200112)44:123.0.CO;2-C; Kwak HB, Ha H, Kim HN, et al. Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum. 2008;58:1332-42. doi:10.1002/art.23372; Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol. 2001;98(1):39-45. doi:10.1006/clim.2000.4957; Hueber W, Tomooka BH, Zhao XY, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis. 2007;66(6):712-9.; Kokkonen H, Soderstrom I, Rocklov J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(2):383-91.; Eriksson C, Rantapaa-Dahlqvist S, Sundqvist KG. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2013;42(4):260-5.; Pandya J, Lundell A, Andersson K, et al. Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. Arthritis Res Ther. 2017;19:20.; Ichikawa T, Kageyama Y, Kobayashi H, et al. Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis. Rheumatol Int. 2010;30(6):725-30. doi:10.1007/s00296-009-1356-y; Kuan WP, Tam LS, Wong CK, et al. CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol. 2010;37(2):257-64.; Van Hooij A, Boeters D, Tjon Kon Fat E, et al. Longitudinal IP-10 serum levels are associated with the course of disease activity and remission in rheumatoid arthritis. Clin Vaccine Immunol. 2017;24(8):e00060-17. doi:10.1128/CVI.00060-17; Yellin M, Paliienko I, Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of mdx-1100, a fully human anti-cxcl10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(6):1730-9.; Heller EA, Liu E, Tager AM, et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation. 2006;113:2301-12. doi:10.1161/CIR-CULATIONAHA.105.605121; Boyle D, Wei N, Singhal A. The Jak inihibitor Tofacitinib suppresses synovial Jak-stat signalling in rheumatoid arthritis. Arthritis Rheum. 2013;65 Suppl:764.; Han BK, Kuzin I, Gaughan JP, et al. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study. Arthritis Res Ther. 2015;18:93. doi:10.1186/s13075-016-0995-0; Lee J, Kim B, Jong Jin W, et al. Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis. Arthritis Res Ther. 2017;19:163.; Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722-7.; Minaur NJ, Jacoby RK, Cosh JA, et al. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol. 2004;69 Suppl:3-8.; Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis – interstitial lung disease-associated mortality. Am J Resp Crit Care Med. 2011;183:372-8. doi:10.1164/rccm.201004-0622OC; Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;4:443-8. doi:10.1513/pats.200703-045MS; Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arithritis: a population-based study. Arthritis Rheum. 2010;62:1583-91. doi:10.1002/art.27405; Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56:622-7. doi:10.1136/thorax.56.8.622; Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Resp Crit Care Med. 2012;185:1147-53. doi:10.1164/rccm.201108-1420PP; Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159-66. doi:10.1001/archinternmed.2007.59; Dawson JK, Fewins HE, Desmond J, et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61:517-21.; Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60:2183-92. doi:10.1002/art.24631; Shimizu S, Yoshinouchi T, Niimi T, et al. Differing distributions of CXCR3- and CCR4-positive cells among types of interstitial pneumonia associated with collagen vascular diseases. Virchows Arch. 2007;450:51-8. doi:10.1007/s00428-006-0330-2; Chen J, Doyle T, Liu Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2015;67(1):28-38. doi:10.1002/art.38904; Abji F, Remy A, Pollock R, et al. CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheuma. 2016;68:2911-6. doi:10.1002/art.39800; Авдеева АС, Новиков АА, Александрова ЕН и др. Значение показателей цитокинового профиля при оценке эффективности терапии моноклональными антителами; к рецепторам интерлейкина-6 при ревматоидном артрите. Клиническая медицина. 2014;(1):28-34 [Avdeeva AS; Novikov AA, Aleksandrova EN, et al. The value of cytokine profile in evaluating the effectiveness of monoclonal antibodies to interleukin-6 receptors in rheumatoid arthritis. Klinicheskaya Meditsina. 2014;(1):28-34 (In Russ.)].; Авдеева АС, Александрова ЕН, Новиков АА и др. Сравнение влияния терапии ритуксимабом и тоцилизумабом на активность и лабораторные показатели у больных ревматоидным артритом. Клиническая фармакология; и терапия. 2014;(1):25-32 [Avdeeva AS, Aleksandrova EN, Novikov AA, et al. Comparison of the effect of rituximab and tocilizumab on activity and laboratory parameters in patients with rheumatoid arthritis. Klinicheskaya Farmakologiya i Terapiya. 2014;(1):25-32 (In Russ.)].; Авдеева АС, Новиков АА, Александрова ЕН и др. Динамика уровней цитокинов на фоне терапии метотрексатом и адалимумабом у пациентов с ранним ревматоидным артритом (исследование РЕМАРКА). Научно-практическая ревматология. 2014;52(3):254-63 [Avdeeva AS, Novikov AA, Aleksandrova EN, et al. Changes of cytokine levels during therapy with methotrexate and adalimumab in patients with early rheumatoid arthritis (REMARCA study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):254-63 (In Russ.)]. doi:10.14412/1995-4484-2014-254-262; Авдеева АС, Новиков АА, Александрова ЕН и др. Взаимосвязь показателей цитокинового профиля с активностью заболевания и уровнем аутоантител при раннем ревматоидном артрите (РА). Клиническая лабораторная диагностика. 2014;59(9):37 [Avdeeva AS, Novikov AA, Aleksandrova EN, et al. Interrelation of cytokine profile with disease activity and level of autoantibodies in early rheumatoid arthritis (RA). Klinicheskaya Laboratornaya Diagnostika. 2014;59(9):37 (In Russ.)].; https://rsp.mediar-press.net/rsp/article/view/2471

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2471
https://doi.org/10.14412/1995-4484-2017-655-661

المؤلفون: A. Abramkin A., T. Lisitsyna A., D. Veltishchev Yu., O. Seravina F., O. Kovalevskaya B., S. Glukhova I., E. Nasonov L., А. Абрамкин А., Т. Лисицына А., Д. Вельтищев Ю., О. Серавина Ф., О. Ковалевская Б., С. Глухова И., Е. Насонов Л.

المصدر: Rheumatology Science and Practice; Vol 56, No 4 (2018); 439-448 ; Научно-практическая ревматология; Vol 56, No 4 (2018); 439-448 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20184

مصطلحات موضوعية: rheumatoid arthritis, mental disorders, disease-modifying antirheumatic drugs, biological agents, efficiency of therapy, predictors, psychopharmacotherapy, therapy adherence, ревматоидный артрит, психические расстройства, базисные противовоспалительные препараты, генно-инженерные биологические препараты, эффективность терапии, предикторы, психофармакотерапия, приверженность лечению

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2589/1732; Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016;353:i1777. doi:10.1136/bmj.i1777; Donahue KE, Gartlehner G, Jonas DE, et al. Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis. Ann Intern Med. 2008;148(2):124. doi:10.7326/0003-4819-148-2-200801150-00192; Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1113-36. doi:10.1136/annrheumdis-2016-210713; Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014;6(6):CD000957. doi:10.1002/14651858.CD000957.pub2; Wijbrandts CA, Tak PP. Prediction of Response to Targeted Treatment in Rheumatoid Arthritis. Mayo Clin Proc. 2017;92(7):1129-43. doi:10.1016/j.mayocp.2017.05.009; Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2015;55(3):kev374.; Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol. 2017;13(8):503-10. doi:10.1038/nrrheum.2017.81; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. doi:10.1016/S0140-6736(16)30173-8; Лисицына ТА, Вельтищев ДЮ. Психические расстройства; у больных ревматическими заболеваниями: диагностика; и лечение. Научно-практическая ревматология. 2015;53(5):512-21 doi:10.14412/1995-4484-2015-512-521; Matcham F, Norton S, Scott DL, et al. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford). 2015;55(2):269-78. doi:10.1093/rheumatology/kev306; Lu M-C, Guo H-R, Lin M-C, et al. Bidirectional associations between rheumatoid arthritis and depression: a nationwide longitudinal study. Sci Rep. 2016;6(February):20647. doi:10.1038/srep20647; Benka J, Nagyova I, Rosenberger J, et al. Social participation in early and established rheumatoid arthritis patients. Disabil Rehabil. 2016;38(12):1172-9. doi:10.3109/09638288.2015.1076071; Feldthusen C, Grimby-Ekman A, Forsblad-D’Elia H, et al. Explanatory factors and predictors of fatigue in persons with rheumatoid arthritis: A longitudinal study. J Rehabil Med. 2016;48(5):469-76. doi:10.2340/16501977-2090; Curtis JR, Bykerk VP, Aassi M, et al. Adherence and persistence with methotrexate in rheumatoid arthritis: A systematic review. J Rheumatol. 2016;43(11):1997-2009. doi:10.3899/jrheum.151212; Markenson JA, Koenig AS, Feng JY, et al. Comparison of Physician and Patient Global Assessments Over Time in Patients With Rheumatoid Arthritis. J Clin Rheumatol. 2013;19(6):317-23. doi:10.1097/RHU.0b013e3182a2164f; Euesden J, Matcham F, Hotopf M, et al. The Relationship Between Mental Health, Disease Severity, and Genetic Risk for Depression in Early Rheumatoid Arthritis. Psychosom Med. 2017;79(6):638-45. doi:10.1097/PSY.0000000000000462; Rathbun AM, Harrold LR, Reed GW. Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2015;67(6):765-75. doi:10.1002/acr.22515; Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. doi:10.1002/art.27584; Насонов ЕЛ. Ревматология. Российские клинические рекомендации. ГЭОТАР-Медиа: Москва, 2017.; Амирджанова ВН, Койлубаева ГН, Горячев ДВ и др. Валида-ция русскоязычной версии Health Assessment Questionnaire (HAQ). Научно-практическая ревматология. 2004;42(2):59-64; Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745-57, vii–viii. doi:10.1016/j.rdc.2009.10.001; Van Gestel AM, Prevoo ML, van’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40. doi:10.1002/art.1780390105; Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70. doi:10.1111/j.1600-0447.1983.tb09716.x; Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. doi:10.1111/j.2044-8341.1959.tb00467.x; Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9. doi:10.1192/bjp.134.4.382; Лурия АР. Высшие корковые функции человека и их нарушения при локальных поражениях мозга. 2-е изд. Москва: Издательство МГУ; 1962.; Херсонский БГ. Метод пиктограмм в психодиагностике пси-хических заболеваний. Киев: Здоровья; 1988; World Health Organization. The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research. 1993: xiii+248p. doi:10.1002/1520-6505(2000)9:53.3.CO;2-P; Зейгарник БВ. Патология мышления. 2-е изд. Москва: Издательство МГУ; 1962; Простые аналогии. Альманах психологических тестов. 3-е изд. Москва: «КСП»; 1995.; Рубинштейн СЯ; Бутенко Г, редактор. Экспериментальные методики патопсихологии и опыт применения их в клинике. Москва: Издательство Института психотерапии; 2010; American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders?: DSM-IV-TR. American Psychiatric Association; 2000.; Герасимов АН. Медицинская статистика: учебное пособие. Москва: Медицинское информационное агентство; 2007; Абрамкин АА. Влияние коморбидных психических расстройств на эффективность терапии у больных ревматоидным артритом. Научно-практическая ревматология. 2016;54(3):339-45 doi:10.14412/1995-4484-2016-339-34; Lee K-E, Choi S-E, Xu H, et al. HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis. Rheumatol Int. 2017;37(12):2027-34. doi:10.1007/s00296-017-3833-z; Katchamart W, Johnson S, Lin H-JL, et al. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken). 2010;62(8):1128-43. doi:10.1002/acr.20188; Yu MB, Firek A, Langridge WHR. Predicting methotrexate resistance in rheumatoid arthritis patients. Inflammopharmacology. March 12, 2018:1-10. doi:10.1007/s10787-018-0459-z; Romao VC, Vital EM, Fonseca JE, et al. Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? Arthritis Res Ther. 2017;19(1):239. doi:10.1186/s13075-017-1445-3; Hamann P, Holland R, Hyrich K, et al. Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. Arthritis Care Res (Hoboken). 2017;69(6):783-93. doi:10.1002/acr.23016; Kleinert S, Tony HP, Krause A, et al. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: Data from a German noninterventional observational study. Rheumatol Int. 2012;32(9):2759-67. doi:10.1007/s00296-011-2033-5; Mikuls TR, O’Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004;50(12):3776-82. doi:10.1002/art.20659; Pers Y-M, Fortunet C, Constant E, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford). 2014;53(1):76-84. doi:10.1093/rheumatology/ket301; Albrecht K, Luque Ramos A, Hoffmann F, et al. High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data. Rheumatology (Oxford). 2017;57(2):329-36. doi:10.1007/s00393-017-0294-4; Asai S, Fujibayashi T, Oguchi T, et al. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study. Mod Rheumatol. March 4, 2017:1-6. doi:10.1080/14397595.2017.1332558; Akter N, Qureshi NK, Hoque MA, et al. Extra-Articular Manifestations of Rheumatoid Arthritis & its relation with Treatment Outcome: a tertiary care hospital experience. KYAMC J. 2015;6(1):570-3. doi:10.3329/kyamcj.v6i1.32784; Soliman MM, Hyrich KL, Lunt M, et al. Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. J Rheumatol. 2012;39(2):240-6. doi:10.3899/jrheum.110610; McWilliams DF, Ferguson E, Young A, et al. Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data. Arthritis Res Ther. 2016;18(1):295. doi:10.1186/s13075-016-1186-8; Scheiman-Elazary A, Duan L, Shourt C, et al. The rate of adherence to antiarthritis medications and associated factors among patients with rheumatoid arthritis: A systematic literature review and metaanalysis. J Rheumatol. 2016;43(3):512-23. doi:10.3899/jrheum.141371; Joshi K, Lin J, Lingohr-Smith M, et al. Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States. J Clin Psychopharmacol. 2016;36(5):429-35.; Gray R, Bressington D, Ivanecka A, et al. Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis. BMC Psychiatry. 2016;16:90. doi:10.1186/s12888-016-0801-1; Jain A, Bhadauria D. Evaluation of efficacy of fluoxetine in the management of major depression and arthritis in patients of Rheumatoid Arthritis. Ind J Rheumatol. 2013;8(4):165-9. doi:10.1016/j.injr.2013.08.001; Kekow J, Moots R, Khandker R, et al. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford). 2011;50(2):401-9. doi:10.1093/rheumatology/keq327; Karpouzas GA, Draper T, Moran R, et al. Trends in functional disability and determinants of clinically meaningful change over time in Hispanics with Rheumatoid arthritis in the United States. Arthritis Care Res. 2016;69(2):294-8. doi:10.1002/acr.22924; Fiest KM, Hitchon CA, Bernstein CN, et al. Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. J Clin Rheumatol. 2017;00(00):1. doi:10.1097/RHU.0000000000000489; https://rsp.mediar-press.net/rsp/article/view/2589

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2589
https://doi.org/10.14412/1995-4484-2018-439-448